RPH3A antibody - N-terminal region (AVARP13088_P050)
- Known as:
- RPH3A (anti-) - N-terminal region (AVARP13088_P050)
- Catalog number:
- avarp13088_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- RPH3A antibody - N-terminal region (AVARP13088_P050)
Related genes to: RPH3A antibody - N-terminal region (AVARP13088_P050)
- Gene:
- RPH3A NIH gene
- Name:
- rabphilin 3A
- Previous symbol:
- -
- Synonyms:
- KIAA0985, rabphilin, exophilin-1
- Chromosome:
- 12q24.13
- Locus Type:
- gene with protein product
- Date approved:
- 2003-12-10
- Date modifiied:
- 2015-09-07
Related products to: RPH3A antibody - N-terminal region (AVARP13088_P050)
Related articles to: RPH3A antibody - N-terminal region (AVARP13088_P050)
- Cerebral edema (CE) is a major determinant of poor outcomes after traumatic brain injury (TBI). CE affects approximately 60% of patients with mass lesions on head computed tomography (hCT) and confers a tenfold increase in mortality. Despite this burden, no validated biomarkers exist to identify patients at risk for early CE worsening or to elucidate the biological processes underlying divergent edema trajectories. We conducted high-throughput plasma proteomic profiling in a prospective moderate-severe TBI cohort with evidence of intracranial blood on the initial post-injury hCT scan (n=123 patients) to (1) identify a clinically feasible set of biomarkers plus a predictive model that could be used to assess CE risk at admission, and (2) conduct a mechanistic, hypothesis-generating analysis to identify the molecular networks involved in CE progression in the first hours post-injury. Plasma collected within 3 hours of injury was analyzed using the Olink Explore platform (5394 proteins), and patients underwent head CT imaging upon presentation and at 6 hours. Two complementary analytic pathways, reflecting the study's two goals, were pursued in parallel. First, logistic regression with false discovery rate (FDR) correction identified a conservative 12-protein set associated with baseline CE. When combined with targeted clinical variables (i.e., age, sex, admission GCS, pupil reactivity, admission glucose, admission alcohol), this panel supported high-performing supervised classifiers for predicting CE worsening by 6 hours post-baseline scan (best model: XGBoost, AUC = 0.78; recall = 0.83). Second, a broader 60-protein panel, selected via bootstrapped elastic-net regression, was used to interrogate the mechanistic architecture of CE worsening using random forest SHAP attribution and protein-protein interaction modeling. Proteomic signatures diverged sharply between patients whose CE did and did not worsen. The CE worsening group was characterized by a coherent neuronal-synaptic injury axis dominated by ELAVL4, CEND1, NEFL, NECAB2, GFAP, CHGB, RPH3A, HPCAL4, and HOMER1, proteins involved in neuronal structural integrity, vesicular trafficking, synaptic vesicle cycling, calcium signaling, and axonal degeneration. These reciprocal proteomic states suggest that early edema progression may be driven by coordinated disruption of neuronal and synaptic resilience programs. Together, these findings suggest (1) a hyperacute biomarker panel plus predictive model with potential for prospective validation and (2) mechanistic evidence for a distinct neuronal-synaptic injury network that associates with early edema worsening after TBI. - Source: PubMed
Publication date: 2026/05/26
Radabaugh Hannah LAbdelhak AhmedNing KiarraJha Ruchira MRowell Susan EPollock Jeffrey MMendoza EsmeraldaRojas Valencia Luisa MFerguson Adam RHinson H E - : Gaucher disease (GD) arises from pathogenic variants in the gene and is known for its wide range of clinical presentations-a variability that genotype alone cannot adequately account for. : This study aimed to explore transcriptomic factors that might help explain why two genetically identical twins with type 1 GD developed noticeably different clinical outcomes. : We isolated peripheral blood mononuclear cells from both twins and two age-matched controls, then differentiated them into macrophages in vitro before conducting RNA sequencing. Gene expression differences were analyzed using established bioinformatics pipelines, and a subset of genes were subsequently assessed by quantitative real-time PCR (qRT-PCR) to confirm the sequencing findings. : Both twins shared a GD-associated transcriptional signature broadly reflecting immune activation and lysosomal stress. Interestingly, the twin who experienced systemic complications had a relative enrichment of interferon-responsive transcripts, while the less severely affected twin showed more pronounced suppression of small nucleolar RNA clusters. That said, neither difference held up after correcting for multiple comparisons, so these patterns are best viewed as exploratory trends rather than definitive findings. The qRT-PCR results lend partial support to this picture: stress- and immune-related genes (, , ) trended toward higher expression in patients versus controls, and interferon-stimulated genes (, , ) were more elevated in M2 than in M1. : Taken together, these findings suggest that factors beyond genetics-whether epigenetic, environmental, or otherwise-may play a meaningful role in shaping how GD manifests differently even between individuals with identical DNA. Although the data are preliminary, they point to transcriptomic profiling, paired with targeted validation, as a useful starting point for building hypotheses about why this disease looks so different from one patient to the next, even when the underlying mutation is the same. - Source: PubMed
Publication date: 2026/04/29
İnci AslıAydoğdu Demirel SümeyyeErgin Filiz Başak CengizBiberoğlu GürselOkur İlyasEzgü Fatih SüheylTümer LeylaÖktem Rıdvan MuratDökmeci Serap - Human neural organoids (NOs) provide a powerful platform for investigating synaptic development and dysfunction during early neurodevelopment. However, methodologies for isolating functional synaptic structures from these models remain limited. Here, we present a differential centrifugation protocol enabling the enrichment of growth cone particles (GCPs) and immature synaptosomes from air-liquid interface cerebral organoids (ALI-COs) at distinct developmental stages (Day 90 and 150). Notably, the method avoids density gradients, requires minimal starting material while maintaining reproducibility across human and murine tissues. Quantitative proteomic profiling revealed significant enrichment of growth cone markers (e.g., GAP43) and classical synaptosomal proteins (e.g., PCLO, BSN, SYN1). Transmission electron microscopy (TEM) confirmed the presence of membrane-enclosed GCPs with fibrous content and mitochondria in Day 90 isolates, and immature synaptosomes containing synaptic vesicles on day 150. Functional viability of both types of synaptic structures was demonstrated through KCl-induced depolarization, which triggered phosphorylation changes in growth cone proteins (GAP43, MARCKS, MARCKSL1), cytoskeletal regulators (DCLK1, SHTN1, MARK4, MAP1B) and protein kinases (CAMK2G, PRKCE) in Day 90 GCPs, as well as classical synaptic vesicle cycle proteins (SYN1, DNM1, RPH3A) at Day 150. Overall, this study establishes a centrifugation-based protocol for isolating growth cones and immature synapses from human organoids, capturing key stages of synaptic development and enabling scalable, patient-compatible models to study synaptic function and dysfunction in neurodevelopmental and neurodegenerative disorders. - Source: PubMed
Øhlenschlæger Marie SCriscuolo LucreziaJensen PiaLloyd-Davies Sánchez Daniel JSutcliffe MagdalenaBhosale SantoshBogetofte HelleTahir MuhammadJakobsen Lene APihl MariaBrewer JonathanSchwämmle VeitPoulsen Frantz RFreude KristineLancaster Madeline ARobinson Phillip JLarsen Martin R - Spinocerebellar Ataxia type 2 (SCA2) and Amyotrophic Lateral Sclerosis type 13 (ALS13) are triggered by polyglutamine expansion in Ataxin-2 (ATXN2). To understand these neurodegenerative disorders at the molecular level, the brains of 10-month-old -CAG100-knockin mice were analyzed as microglial, astroglial and neuronal fractions via global RNA sequencing. Data were validated by comparison with the spinal cord oligonucleotide microarray profile or filtered by RNA-seq consistency. Here, we show that the mutation causes a massive inflammatory response in microglia and a reciprocal loss of neuronal transcripts in glial fractions, suggesting severe synapse loss. Beyond these general neurodegenerative signs, we identify pathognomonic changes in the machinery for protein translation and RNA splicing. Glial fractions showed upregulation of (to 2082%), , , , , , , , and as an unspecific neuroinflammatory signature, versus downregulation of axonal (to <19%), and synaptic , , , and mRNAs correlating with circuit disconnection. In all fractions, reductions in , , and were noted versus disease-specific inductions of ribosomal subunits, presumably mirroring the partial loss-of-function of ATXN2 as RNA translation modulator. Selective accumulations of embryonic factors and versus downregulation of adult specify the mutation impact on splicing and translation elongation. As a potential underpinning of toxic gain-of-function, the proteostasis transcript appeared increased in astroglial and microglial fractions. These transcriptome data suggest altered ribosomal and spliceosome machinery, with massive microgliosis versus mild astrogliosis, at the core of SCA2 and ALS13. - Source: PubMed
Publication date: 2026/04/15
Auburger GeorgKandi Arvind ReddyVutukuri RajkumarAlmaguer-Mederos Luis-EnriqueGispert SuzanaSen Nesli-EceKey Jana - Inhibition of voltage-gated potassium channel Kv1.3 is a therapeutic strategy to curb microglia-mediated neuroinflammation in neurodegeneration, although the cellular and signaling mechanisms of disease-modification by Kv1.3 blockers are unclear. In this study, we delineate protective mechanisms of Kv1.3 blockade in a mouse model of Alzheimer's disease (AD) pathology using comprehensive transcriptomics and proteomics profiling of brain, corresponding with neuropathological effects of two translationally relevant Kv1.3 blockers, namely small molecule PAP-1 and peptide ShK-223. Following 3 months of treatment, both molecules reduced Ab plaque burden. Single nuclear RNA seq (snRNA seq) of brain nuclei showed that PAP-1 disproportionately impacted oligodendrocytes and microglia and increased crosstalk between neurons and astrocytes with endothelial cells. In contrast, ShK-223 had pronounced effects on glutamatergic neurons and astrocytes. Both blockers increased expression of myelination genes in oligodendrocytes and synaptic genes in neurons. Neuroprotective effects of PAP-1 were further confirmed by bulk brain transcriptomics and proteomics whereby PAP-1 increased levels of synaptic, cognitive resilience and mitochondrial proteins, while decreasing glial and immune pathways including STAT1/3 phosphorylation. Using proximity labeling and co-immunoprecipitation, we found that Kv1.3 interacts with STAT1/3 in microglia. Using microglial cell lines and primary microglia, we discovered a preferential functional coupling between Kv1.3 and type 2 but not type 1 IFN signaling. Brain-level disease modification by Kv1.3 blockade was reflected in the cerebrospinal fluid (CSF) via reduced levels of neurofilament-light (NEFL) and resilience protein RPH3A, both of which are increased in human AD CSF. Together, this study demonstrates functional links between Kv1.3 channels and type 2 IFN signaling and reveals distinct cellular effects of Kv1.3 blockers in AD pathology that correspond with reduced neuropathology and neuroinflammation, augmentation of resilience and neuro-vascular pathways, along with biomarkers of therapeutic effect. - Source: PubMed
Publication date: 2025/12/25
Kumari RashmiBowen ChristineSrivastava UpasnaBrandelli Amanda DabdabKumar PrateekKour DilpreetMalepati SnehaJang Wooyoung EricBromwich MarkZeng HollisSing AnsonSloan Steven AWulff HeikeRangaraju Srikant